These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 32010177)

  • 1. Targeted Inhibition of miR-221/222 Promotes Cell Sensitivity to Cisplatin in Triple-Negative Breast Cancer MDA-MB-231 Cells.
    Li S; Li Q; Lü J; Zhao Q; Li D; Shen L; Wang Z; Liu J; Xie D; Cho WC; Xu S; Yu Z
    Front Genet; 2019; 10():1278. PubMed ID: 32010177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cisplatin-resistant MDA-MB-231 Cell-derived Exosomes Increase the Resistance of Recipient Cells in an Exosomal miR-423-5p-dependent Manner.
    Wang B; Zhang Y; Ye M; Wu J; Ma L; Chen H
    Curr Drug Metab; 2019; 20(10):804-814. PubMed ID: 31424364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
    Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
    Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. miR-31-5p may enhance the efficacy of chemotherapy with Taxol and cisplatin in TNBC.
    Shen X; Lei J; Du L
    Exp Ther Med; 2020 Jan; 19(1):375-383. PubMed ID: 31853314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long noncoding RNA HCP5 contributes to cisplatin resistance in human triple-negative breast cancer via regulation of PTEN expression.
    Wu J; Chen H; Ye M; Wang B; Zhang Y; Sheng J; Meng T; Chen H
    Biomed Pharmacother; 2019 Jul; 115():108869. PubMed ID: 31028999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long non-coding RNA TUG1 sponges miR-197 to enhance cisplatin sensitivity in triple negative breast cancer.
    Tang T; Cheng Y; She Q; Jiang Y; Chen Y; Yang W; Li Y
    Biomed Pharmacother; 2018 Nov; 107():338-346. PubMed ID: 30098551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overexpression of microRNA-620 facilitates the resistance of triple negative breast cancer cells to gemcitabine treatment by targeting DCTD.
    Wu C; Zhao A; Tan T; Wang Y; Shen Z
    Exp Ther Med; 2019 Jul; 18(1):550-558. PubMed ID: 31258693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. miR-1207-5p regulates the sensitivity of triple-negative breast cancer cells to Taxol treatment via the suppression of LZTS1 expression.
    Hou X; Niu Z; Liu L; Guo Q; Li H; Yang X; Zhang X
    Oncol Lett; 2019 Jan; 17(1):990-998. PubMed ID: 30655858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apatinib enhanced anti-tumor activity of cisplatin on triple-negative breast cancer through inhibition of VEGFR-2.
    Gao Z; Shi M; Wang Y; Chen J; Ou Y
    Pathol Res Pract; 2019 Jul; 215(7):152422. PubMed ID: 31079851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MiR-199a-3p enhances breast cancer cell sensitivity to cisplatin by downregulating TFAM (TFAM).
    Fan X; Zhou S; Zheng M; Deng X; Yi Y; Huang T
    Biomed Pharmacother; 2017 Apr; 88():507-514. PubMed ID: 28126676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effect of miR-342-3p on chemotherapy sensitivity in triple-negative breast cancer].
    Ma T; Zhang J; Wu J; Tang J
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2014 May; 39(5):488-95. PubMed ID: 24921394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Formononetin ameliorates the drug resistance of Taxol resistant triple negative breast cancer by inhibiting autophagy.
    Li T; Zhang S; Chen F; Hu J; Yuan S; Li C; Wang X; Zhang W; Tang R
    Am J Transl Res; 2021; 13(2):497-514. PubMed ID: 33594306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miRNA-21 promotes proliferation and invasion of triple-negative breast cancer cells through targeting PTEN.
    Fang H; Xie J; Zhang M; Zhao Z; Wan Y; Yao Y
    Am J Transl Res; 2017; 9(3):953-961. PubMed ID: 28386324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. miR-381 overcomes cisplatin resistance in breast cancer by targeting MDR1.
    Yi D; Xu L; Wang R; Lu X; Sang J
    Cell Biol Int; 2019 Jan; 43(1):12-21. PubMed ID: 30444043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNA-223 Increases the Sensitivity of Triple-Negative Breast Cancer Stem Cells to TRAIL-Induced Apoptosis by Targeting HAX-1.
    Sun X; Li Y; Zheng M; Zuo W; Zheng W
    PLoS One; 2016; 11(9):e0162754. PubMed ID: 27618431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MiR-153 promotes breast cancer cell apoptosis by targeting HECTD3.
    Wu X; Li L; Li Y; Liu Z
    Am J Cancer Res; 2016; 6(7):1563-71. PubMed ID: 27508098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eribulin upregulates miR-195 expression and downregulates Wnt3a expression in non-basal-like type of triple-negative breast cancer cell MDA-MB-231.
    Furuya K; Sasaki A; Tsunoda Y; Tsuji M; Udaka Y; Oyamada H; Tsuchiya H; Oguchi K
    Hum Cell; 2016 Apr; 29(2):76-82. PubMed ID: 26573286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38.
    Gohr K; Hamacher A; Engelke LH; Kassack MU
    BMC Cancer; 2017 Nov; 17(1):711. PubMed ID: 29100507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation.
    Andey T; Sudhakar G; Marepally S; Patel A; Banerjee R; Singh M
    Mol Pharm; 2015 Apr; 12(4):1105-20. PubMed ID: 25661724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of the miR-141/200c cluster promotes the migratory and invasive ability of triple-negative breast cancer cells through the activation of the FAK and PI3K/AKT signaling pathways by secreting VEGF-A.
    Choi SK; Kim HS; Jin T; Hwang EH; Jung M; Moon WK
    BMC Cancer; 2016 Aug; 16():570. PubMed ID: 27484639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.